A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-27

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery. However, in recent years, there has been research into the potential benefit of administering RT prior to surgery in a neoadjuvant manner. Given that these studies have shown promising results, it is logical to think that certain patients could benefit from exclusive RT treatment, thereby avoiding surgery and its possible sequelae. This study is a phase I dose-escalation clinical trial with sequential assignment, open-label, in which five different doses (20Gy, 23Gy, 26Gy, 28Gy, and 30Gy) will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique.

The aim of the study is to determine the maximum tolerated dose (MTD) based on acute toxicity, which will allow us to proceed with a phase II clinical trial to confirm efficacy and assess the late toxicity of the treatment. Secondary objectives include assessing the pathological response via core needle biopsy (CNB), radiological response, quality of life, and cosmesis. Additionally, molecular studies will be conducted on tissue and through liquid biopsy; pre- and post-treatment, we aim to identify mutations and predictors of response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intraoperative Radiotherapy After Local Recurrence in Breast Cancer

NCT02386371

Breast Carcinoma

COMPLETED NA

Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy

NCT06596018

Breast Adenocarcinoma

RECRUITING PHASE1/PHASE2

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579

Estrogen Receptor Negative HER2 Positive Breast Carcinoma HER2/Neu Negative +9 more

RECRUITING NA

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557

Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 Metastatic Breast Carcinoma Metastatic Malignant Neoplasm in the Bone +6 more

COMPLETED PHASE2/PHASE3

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555

Bilateral Breast Carcinoma HER2-Negative Breast Carcinoma Localized Breast Carcinoma +2 more

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Early Stage Breast Cancer (Stage 1-3) SBRT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Treatment tolerance will be the basis for allowing us to progress to the next dose level.

Dose-limiting toxicity (DLT) will be defined as a G3-G4 toxicity or G2 in cases of hypo/hyperpigmentation according to the CTCAE v5.0 scale, assessing the following items: induration, ulceration, pruritus, pigmentation changes, and fatigue. If, at 3 months post-RT at the initial dose level, none of the patients present a DLT, three new patients will receive RT at the next dose level. However, if any patient in a group presents a DLT, three additional patients will be added at the same dose level. Dose escalation will continue up to 30Gy unless \>33% of patients in a single dose group experience a DLT.

If \>33% of patients at a dose level experience a DLT, the study will end, and the dose level immediately below this will be selected to design the phase II of the study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type RADIATION

30Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years of age
* Female gender
* ECOG score 0-2
* Positive biopsy for invasive non-lobular breast tumor histology
* Tumor \< 3 cm in diameter as measured by MRI or contrast mammography
* Tumor located ≥ 0.5 cm from the skin or rib cage, clinically or radiologically
* Positive estrogen and/or progesterone receptors
* HER2 negative
* No lymphovascular invasion in the biopsy
* Tumor must be clinically and radiologically N0 (no lymph node involvement). If a suspicious lymph node is seen, it must be biopsied and show a negative result
* Patient weight below 220 kg (weight limit for the treatment table)
* Ability to tolerate the supine position for 20 minutes during treatment
* Able to undergo MRI and/or contrast mammography
* Not pregnant; women of childbearing potential will undergo a pregnancy test to rule this out
* Contraindication to or refusal of surgical treatment, which must be explicitly documented in the medical record.

Exclusion Criteria

* Under 18 years of age
* Male gender
* ECOG score 3-4
* Positive biopsy for invasive lobular carcinoma or ductal carcinoma in situ
* Tumor ≥ 3 cm in diameter as measured by MRI
* Tumor located \< 0.5 cm from the skin or rib cage, clinically or radiologically
* Negative estrogen and progesterone receptors
* HER2 positive
* Presence of lymphovascular invasion in the biopsy
* Positive BRCA mutation
* Multicentric tumor
* Tumor with positive axillary lymph nodes
* Patients with metastatic disease
* History of previous breast cancer in the same breast
* Previous thoracic radiotherapy
* Pregnant or actively breastfeeding
* Unable to undergo MRI or contrast mammography
* Unable to tolerate the supine position
* Patient with breast implants
* Patients with pacemakers
* Scleroderma, lupus, or other connective tissue diseases with active flares
* Inability to understand and sign the informed consent

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No